Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 128c
Tweet
Share
E-mail
Get Alerts FULC Hot Sheet
Join SI Premium – FREE
Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of $0.87, $1.28 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $80 million versus the consensus estimate of $1.78 million.
For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q4 EPS by 13c; Offers Guidance
- Synopsys (SNPS) Tops Q3 EPS by 24c; offers guidance
- Arcline completes all-cash acquisition of AstroNova at $29 per share
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
